` TLSA (Tiziana Life Sciences Ltd) vs S&P 500 Comparison - Alpha Spread

TLSA
vs
S&P 500

Over the past 12 months, TLSA has significantly outperformed S&P 500, delivering a return of +123% compared to the S&P 500's +14% growth.

Stocks Performance
TLSA vs S&P 500

Loading
TLSA
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
TLSA vs S&P 500

Loading
TLSA
S&P 500
Difference
www.alphaspread.com

Performance By Year
TLSA vs S&P 500

Loading
TLSA
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Tiziana Life Sciences Ltd vs Peers

S&P 500
TLSA
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Tiziana Life Sciences Ltd
Glance View

Market Cap
180.6m USD
Industry
Biotechnology

Tiziana Life Sciences Ltd. engages in the research and development of biotechnological and pharmaceutical products. The firm is focused on the discovery and development of molecules and related diagnostics to treat unmet medical needs in oncology and immunology. Its lead product candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501), and Milciclib TZLS-201. Foralumab (TZLS-401) is a fully human engineered anti-human cluster of differentiation 3 (CD3) monoclonal antibody (mAb). Foralumab is developed for the treatment of neurodegenerative diseases such as progressive Multiple Sclerosis (MS), and Crohn’s disease. The Anti IL-6R mAb (TZLS-501) is a fully human engineered mAb targeting the interleukin-6 receptor (IL-6R). Anti-IL-6R antibody can be used in combination with Foralumab or other anti-inflammatory and anti-infective agents as therapy for COVID-19 and oncology indications. The firm has developed Milciclib TZLS-201 for the treatment of hepatocellular carcinoma (HCC).

TLSA Intrinsic Value
0.1 USD
Overvaluation 94%
Intrinsic Value
Price
Back to Top